Staar Surgical Company is a pioneering developer, manufacturer, and marketer of implantable miniature lenses, primarily used in vision correction procedures
Specializing in advanced ophthalmic technologies, the company focuses on innovative solutions for conditions such as myopia and presbyopia. Staar Surgical aims to enhance patient satisfaction and visual outcomes by providing high-quality, innovative products that are designed to improve the overall eye health and well-being of individuals seeking surgical options for improved eyesight. Through its commitment to research and development, the company continues to advance the field of vision correction and expand its global presence in the ophthalmic medical device market.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
STAAR Surgical reports Q1 2024 net sales surpassing $77 million, with U.S. ICL sales hitting $5 million, the highest since FDA approval in 2022. CEO anticipates fiscal 2024 sales expected at the higher end of $335-340 million outlook.
Shares of STAAR Surgical Company (NASDAQSTAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3% to $44.30 on Thursday.
